Skip to main content
SpringerLink
Log in

Mind the Gap!

Welt ohne Tuberkulose — warum die EndTB-Strategie der WHO so schwierig ist

  • fortbildung
  • Published:
Pneumo News Aims and scope

Mit 1,7 Mio. Todesfällen ist die Tuberkulose (TB) die häufigste Infektionskrankheit und weltweit eine der zehn häufigsten Todesursachen. Die EndTB-Strategie der WHO ist eine ehrgeizige Vision, die TB zu eliminieren. Obwohl das Hauptaugenmerk der Strategie in den Hochinzidenzländern liegt, sind auch Niedriginzidenzländer wie Deutschland mit 5.912 Fällen im Jahr 2016, z. B. aufgrund von Migrationsbewegungen, noch weit von diesem Ziel entfernt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3
4

Literatur

  1. Global tuberculosis report 2017. World Health Organization, Genf, 2017. Licence: CC BY-NC-SA 3.0 IGO

  2. Robert Koch-Institut (RKI). Bericht zur Epidemiologie der Tuberkulose in Deutschland fur 2016. ISBN 978-3-89606-285-7

  3. Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research. An overview in year 3 of the End TB era. Lancet Respir Med. 2018;6(4):299–314

    Article  PubMed  Google Scholar 

  4. Kaufmann SHE, Lange C, Rao M et al. Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review. Lancet Respir Med. 2014;2(4):301–20

    Article  CAS  PubMed  Google Scholar 

  5. Fine PE. Variation in protection by BCG. Implications of and for heterologous immunity. Lancet. 1995;346(8986):1339–45

    Article  CAS  PubMed  Google Scholar 

  6. Rodrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil. The BCG-REVAC cluster-randomised trial. Lancet. 2005;366(9493):1290–5

    Article  PubMed  Google Scholar 

  7. Mangtani P, Abubakar I, Ariti C et al. Protection by BCG vaccine against tuberculosis. A systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–80

    Article  PubMed  Google Scholar 

  8. Scriba TJ, Kaufmann SHE, Henri Lambert P et al. Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines. J Infect Dis. 2016;214(5):659–64

    Article  CAS  PubMed  Google Scholar 

  9. Loxton AG, Knaul JK, Grode L et al. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol. 2017;24(2); pii: e00439–16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gillard P, Yang PC, Danilovits M et al. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis. A phase II randomised study. Tuberculosis. 2016;100:118–27

    Article  CAS  PubMed  Google Scholar 

  11. Clark S, Lanni F, Marinova D et al. Revaccination of Guinea Pigs with the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG‘es Protection Against Tuberculosis. J Infect Dis. 2017;216(5):525–33

    Article  PubMed  Google Scholar 

  12. Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG. A randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lange C, Mandalakas AM, Kalsdorf B et al. Clinical Application of Interferon-γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathog Immun. 2016;1(2):308–29

    Article  PubMed  PubMed Central  Google Scholar 

  14. Schaberg T, Bauer T, Brinkmann F et al. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie. 2017;71(6):325–97

    Article  PubMed  Google Scholar 

  15. Zak DE, Penn-Nicholson A, Scriba TJ et al. A blood RNA signature for tuberculosis disease risk. A prospective cohort study. Lancet. 2017;387(10035):2312–22

    Article  CAS  Google Scholar 

  16. Dowdy DW, Grant AD, Dheda K et al. Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis. J Infect Dis. 2017;216(suppl_6):S654–61

    Article  PubMed  Google Scholar 

  17. Dorman SE, Schumacher SG, Alland D et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance. A prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2016;18(1):76–84

    Article  Google Scholar 

  18. Jafari C, Olaru ID, Daduna F et al. Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods. Eur Respir J. 2018;51(5); https://doi.org/10.1183/13993003.02189-2017

  19. Feiterna-Sperling C, Brinkmann F, Adamczick C et al. S2k-Leitlinie zur Diagnostik, Pravention und Therapie der Tuberkulose im Kindes- und Jugendalter. Pneumologie. 2017;71(10):629–80

    Article  CAS  PubMed  Google Scholar 

  20. Suthar AB, Lawn SD, del Amo J et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV. A systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung. 2010;14(10):1295–302

    CAS  Google Scholar 

  22. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009; 30(4):797–810

    Article  PubMed  Google Scholar 

  23. European AIDS Clinical Society Guidelines. Version 9.0 October 2017; 2017; http://www.eacsociety.org/files/guidelines_9.0-english.pdf

  24. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1):CD000171

  25. Gunther G, {van} Leth F, Alexandru S et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerging Infect Dis. 2015;21(3):409–16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sharma A, Hill A, Kurbatova E et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa. A mathematical modelling study. Lancet Infect Dis. 2017; 7(7):707–15

    Article  Google Scholar 

  27. Tiberi S, Du Plessis N, Walzl G et al. Tuberculosis. Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018; https://doi.org/10.1016/S1473-3099(18)30110-5

  28. Falzon D, Schunemann HJ, Harausz E et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3); https://doi.org/10.1183/13993003.02308-2016

  29. Heyckendorf J, Olaru ID, Ruhwald M, Lange C. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2014;190(4):374–83

    Article  CAS  PubMed  Google Scholar 

  30. Olaru ID, Lange C, Heyckendorf J. Personalized medicine for patients with MDR-TB. J Antimicrob Chemother. 2016;71(4):852–55

    Article  CAS  PubMed  Google Scholar 

  31. Carter DJ, Glaziou P, Lonnroth K et al. The impact of social protection and poverty elimination on global tuberculosis incidence. A statistical modelling analysis of Sustainable Development Goal 1. Lancet Global Health. 2018;6(5):e514–22

    Article  PubMed  Google Scholar 

  32. Murray M, Oxlade O, Lin HH. Modeling social, environmental and biological determinants of tuberculosis. Int J Tuberc Lung Dis. 2011;15Suppl 2:64–70

    Article  PubMed  Google Scholar 

  33. Dorman SE, Schumacher SG, Alland D et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76–84

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Liu F, Du FJ, Jia HY et al. Inadequate values from an interferon-gamma release assay for smear-negative tuberculosis in a high-burden setting. Int J Tuberc Lung Dis. 2014;18(12):1496-501

  35. http://www.pipelinereport.org URL /2017/tbtx; zugegriffen am 3.6.2018

  36. TB Alliance (www.tballiance.org URL ); zugegriffen am 3.6.2018

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik Borstel / Forschungszentrum Borstel, Parkallee 35, 23845, Borstel, Deutschland

    Constanze Born

  2. Medizinische Klinik Borstel, Borstel, Deutschland

    Christoph Lange,  Jan Heyckendorf,  Christian Herzmann,  Helmut J. F. Salzer MPH &  Patricia Sanchéz-Carballo

  3. Abteilung Klinische Infektiologie, Medizinische Klinik Borstel, Borstel, Deutschland

    Christoph Lange,  Jan Heyckendorf,  Christian Herzmann, Hans-Peter Grobbel, Niklas Köhler, Juliane Radloff, Maja Reimann MSc,  Helmut J. F. Salzer MPH &  Patricia Sanchéz-Carballo

  4. Deutsches Zentrum für Infektiologie (DZIF), Klinisches Tuberkulose-Zentrum, Borstel, Deutschland

    Christoph Lange,  Jan Heyckendorf,  Christian Herzmann, Hans-Peter Grobbel, Niklas Köhler, Maja Reimann MSc,  Helmut J. F. Salzer MPH,  Patricia Sanchéz-Carballo & Dagmar Schaub Dipl.-Ing.

  5. International Health/ Infektiologie, Universität zu Lübeck, Lübeck, Deutschland

    Christoph Lange,  Jan Heyckendorf, Niklas Köhler, Maja Reimann MSc &  Helmut J. F. Salzer MPH

  6. Department of Medicine, Karolinska Institut, Stockholm, Sweden

    Christoph Lange

  7. Klinisches Studienzentrum Borstel, Lübeck, Deutschland

    Jan Heyckendorf &  Christian Herzmann

  8. Abteilung für Infektiologie, Universität von Namibia, School of Medicine, Windhoek, Namibia

    Gunar Günther

Authors
  1. Constanze Born
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Heyckendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Herzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gunar Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans-Peter Grobbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Niklas Köhler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Juliane Radloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maja Reimann MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Helmut J. F. Salzer MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Patricia Sanchéz-Carballo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Dagmar Schaub Dipl.-Ing.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Constanze Born.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Born, C., Lange, C., Heyckendorf, J. et al. Welt ohne Tuberkulose — warum die EndTB-Strategie der WHO so schwierig ist. Pneumo News 10, 27–34 (2018). https://doi.org/10.1007/s15033-018-0980-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-018-0980-1

Search

Navigation